Skip to content

Dopamine in Orthostatic Tolerance

Dopamine in Orthostatic Tolerance

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00748228
Enrollment
22
Registered
2008-09-08
Start date
2004-11-30
Completion date
2012-07-31
Last updated
2015-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postural Tachycardia Syndrome

Brief summary

One goal of this study is to determine whether people with different amounts of dopamine-beta-hydroxylase (DBH) have different responses to events that affect blood pressure and heart rate. We will also study whether increasing dietary salt improves symptoms during upright posture. Finally, we will examine whether the dietary sodium level influences serum DBH activity and whether DBH level influences the response to sodium. DBH levels and the function of the sympathetic or involuntary nervous system will be assessed in normal volunteers and in patients with postural tachycardia syndrome (POTS).

Interventions

DIETARY_SUPPLEMENTdietary sodium

10 mEq/day

Sponsors

Vanderbilt University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Upright plasma norepinephrine \> 600 pg/ml, or * An increase in heart rate of \> 30 beats per minute upon standing, and * Withdrawal of all medications for at least 3 days, and * No associated medical illness, and * Age 18 - 60 years old.

Exclusion criteria

* Older than 60 years of age * Routinely taking medications affecting the autonomic nervous system * Any chronic illness (cardiac, pulmonary, endocrine, gastrointestinal, rheumatologic) other than POTS * Anemia (Hct \< 30) * Women of childbearing age who are pregnant or nursing * Unable to give informed consent

Design outcomes

Primary

MeasureTime frame
plasma dopamine-beta-hydroxylaseat enrollment and after tests
plasma dopamineafter tests

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026